Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 7/20 | 0.39 |
| ▸ | ACHE | P22303 | 5/20 | 0.31 |
| ▸ | CNR1 | P21554 | 2/20 | 0.31 |
| ▸ | CNR2 | P34972 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | GPR3 | P46089 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoromethanesulfonic Acid SCHEMBL112169 | 0.93 | KCNH2 (0.44) | KCNH2ACHECNR1CNR2GAA | |
| Trifluoromethanesulfonic Acid SCHEMBL6564917 | 0.85 | KCNH2 (0.40) | KCNH2ACHEGPR3 | |
| Trifluoromethanesulfonic Acid SCHEMBL31564951 | 0.81 | GPR3 (0.38) | KCNH2ACHEGPR3 | |
| Trifluoromethanesulfonic Acid SCHEMBL29402880 | 0.81 | GPR3 (0.38) | KCNH2ACHEGPR3 | |
| Trifluoromethanesulfonic Acid SCHEMBL547976 | 0.81 | GPR3 (0.38) | KCNH2ACHEGPR3 | |
| Trifluoromethanesulfonic Acid SCHEMBL36034 | 0.81 | GPR3 (0.38) | KCNH2ACHEGPR3 | |
| Trifluoromethanesulfonic Acid SCHEMBL31168264 | 0.80 | KCNH2 (0.39) | KCNH2ACHEGPR3 | |
| Trifluoromethanesulfonic Acid SCHEMBL646691 | 0.80 | KCNH2 (0.39) | KCNH2ACHEGPR3 | |
| SCHEMBL1758997 | 0.78 | HTR1B (0.40) | CNR1CNR2GAATDP1L3MBTL1 | |
| SCHEMBL3681320 | 0.76 | KDM4E (0.43) | CNR1CNR2GAATDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080166661-A1 | Method for forming a fine pattern in a semiconductor | HYNIX SEMICONDUCTOR INC. (KR) | 2008-07-10 | — | — | US | disclosed |
| US-6607868-B2 | Dipropargyl acetamide | HYNIX SEMICONDUCTOR INC. (KR) | 2003-08-19 | — | — | US | disclosed |
| US-20020012879-A1 | Novel photoresist monomers, polymers thereof, and photoresist compositions containing the same | HYNIX SEMICONDUCTOR INC. (KR) | 2002-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020012879-A1 | Novel photoresist monomers, polymers thereof, and photoresist compositions containing the same | CDH1, DDAH1, DPEP1 | KCNH2 4478/4885ACHE 3869/4885CNR1 2934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.